AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05753462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2a, SQY51 (cohort 1)
Description: SQY51 is administered by intravenous infusion at dose 1
Study NCT05753462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2a, SQY51 (cohort 2)
Description: SQY51 is administered by intravenous infusion at dose 2.
Study NCT05753462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2a, SQY51 (cohort 3)
Description: SQY51 is administered by intravenous infusion at dose 3.
Study NCT05981326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: biopsy will be performed for multi-omicanalysis at inclusion before initiation of treatment
Study NCT05981326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Centralized blood samples will be performed at inclusion + evaluation visits
Study NCT05981326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Food inquiry + food-frequency questionnaire + physical activity questionnaire will be performed at inclusion
Study NCT06546475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: regular dose or high dose add-on
Study NCT06546475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: regular dose or high dose add-on
Study NCT06414044 — intervention group
Intervention type: DRUG
Intervention: Atogepant 60 mg
Description: Patients using atogepant 60 mg tablet daily as migraine prevention
Study NCT05200312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg capsules administered by mouth twice daily (21-day cycles).
Study NCT05200312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg capsules administered by mouth once daily on Day 1 to Day 10 of each cycle (21-day cycles)
Study NCT05200312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT05100069 — intervention group
Intervention type: DRUG
Intervention: Brigatinib
Description: Brigatinib Tablets
Study NCT05200312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT05200312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT05200312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT05200312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone (or equivalent)
Description: 40 mg/m2 capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
Study NCT06460597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papworth Technique
Description: The Papworth breathing technique is used by respiratory physiotherapists to control and correct breathing. Instead of using the chest, Papworth technique encourages to take more relaxed breathing by using the abdomen. Breathing in slowly through the nose and breathing out through pursed lips as if blowing out a candle. Repeat this cycle for 3-5 times
Study NCT06457399 — intervention group
Intervention type: DRUG
Intervention: Heliox
Description: Treatment for 30 minutes with Heliox from a commercial tank (Oxhelⓒ, Air Liquideⓒ) with a fixed mixture of 70% helium and 30% oxygen with non-rebreather mask or reservoir bag at a flow of 12-15 lpm.
Study NCT06457399 — intervention group
Intervention type: DRUG
Intervention: Oxygen
Description: Treatment for 30 minutes with oxygen at FiO2 of 31% with Venturi mask.
Study NCT06460597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pranayama
Description: Pranayama is an ancient breath technique that originates from yogic practices in India. Sitting comfortably, slowly inhale through the nose and count to five. Direct the breath across the back of the throat as you inhale so the air makes a slight hissing sound keeping the lips sealed, breathe out through the nose and try to match the length of your inhale. The breath should make a noise like waves crashing as you exhale. Continue to inhale and exhale using the same process for 5 to 8 minutes. Aim to do this exercise for 10 to 15 minutes as become more practiced.
Study NCT04940130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanaria® PfSPZ Vaccine
Description: non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).
Study NCT05224154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinent Contingent (AC) Re-Connect
Description: Participants in this group will be able to unblock highly desired, but non-essential (e.g., social networking, shopping, games) applications contingent on meeting goals for smoking abstinence, as verified by meeting carbon monoxide goals (CO\<=6ppm).
Study NCT05224154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Submission Contingent (SC) Re-Connect
Description: Participants in this group will also be able to unblock their applications, but contingent on submitting CO samples and independent of meeting CO goals for smoking abstinence.
Study NCT06071637 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double low-power laser therapy simultaneous applicated
Description: Double low-power laser therapy, with simultaneous application of two wavelengths, red and infrared in in the mouth and neck
Study NCT06071637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double low-power laser therapy simultaneous applicated
Description: Double low-power laser therapy, with simultaneous application of two wavelengths, red and infrared in in the mouth and neck
Study NCT06299579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GD-11 for injection test group
Description: The first dose of GD-11 was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
Study NCT06299579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control group
Description: The first dose of placebo was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
Study NCT04928495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Vitamin C 500 mg / day for ten days
Study NCT04928495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: N-acetylcysteine 1800 mg / day for ten days.
Study NCT04928495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC + Bromhexine (BMX)
Description: NAC + Bromhexine (BMX) 32 mg / day for ten days.
Study NCT04940130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: placebo control- saline
Study NCT05191355 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood test
Description: Blood spot collection for sampling
Study NCT04731623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION904
Description: ION904 will be administered by SC injection.
Study NCT01953211 — intervention group
Intervention type: DRUG
Intervention: combined oral contraceptives
Study NCT04731623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.9% sterile saline) will be administered by SC injection.
Study NCT06355401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20mg
Description: maintenance TAM 20 mg daily for DLBCL who achieve CR after chemotherapy and/or radiotherapy and/or BMT
Study NCT05305820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing treatment and for a six-week period when deemed fit post-surgery.
Study NCT05305820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Participants will be screened for their nutritional health and tailored advice and education will be provided on an individualised basis. An online dietary recall tool will be used to track patients' dietary habits. This will occur from diagnosis until point of surgery and recommence for 6 weeks post-surgery once deemed physically fit.
Study NCT06251869 — intervention group
Intervention type: PROCEDURE
Intervention: total hip arthroplasty with electrocoagulation
Description: using normal technique
Study NCT06251869 — intervention group
Intervention type: PROCEDURE
Intervention: total hip arthroplasty without electrocoagulation
Description: using only scalpel and pean as hemostasis and incision
Study NCT06251869 — intervention group
Intervention type: PROCEDURE
Intervention: total knee arthroplasty with electrocoagulation
Description: using normal technique
Study NCT06251869 — intervention group
Intervention type: PROCEDURE
Intervention: total knee arthroplasty without electrocoagulation
Description: using only scalpel and pean as hemostasis and incision
Study NCT05057143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implants
Description: 3D printed implants
Study NCT05057143 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plates
Description: Titanium plates
Study NCT06168370 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT guided strategy
Description: 1. With signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI are switched from SAPT to apixaban. Patients fulfilling the dose reduction criteria according to the drug label, or with a Clinical Frailty Scale ≥4 will receive 2.5mg bid, patients not meeting these criteria will receive a standard dose of 5mg bid.~2. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI, without another indication for antiplatelet therapy stop their SAPT.~3. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI with another indication for antiplatelet therapy continue life-long SAPT.
Study NCT06114004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 20 MG
Description: After having completed the Phase I part, the recommended dose for Phase II is 60mg Selinexor
Study NCT06114004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days.
Study NCT05371067 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fructose respiratory test
Description: Healthy volunteers will performed a fructose respiratory test in order to evaluate if they are or not fructose malabsorbing. The two population will be compared about their feelings and their micriobiote.
Study NCT05085431 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Assigned Interventions CD19/BCMA CAR T-cells
Description: Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
Study NCT05291416 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: densitometry/ handgrip dynamometer
Description: all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer
Study NCT06523205 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Measurements and Saliva Sample Collection
Description: Saliva samples will be collected from all patients. Clinical parameters will also be recorded. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist will record all clinical parameters using manual probing.~Following sampling, saliva samples will be stored at -80°C until analysis. Concentrations of Tenascin-C, IL-4, IL-6, and IL-1beta will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in saliva samples.
Study NCT04884295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XVR011
Description: Single dose of XVR011 via intravenous (IV) infusion
Study NCT04970069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video on analgesic education
Description: A four minute video informing the patient about opioids.
Study NCT04970069 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Video on general perioperative education
Description: A four minute video informing the patient about general perioperative process.
Study NCT05960838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasling® Quadrant
Description: Immobilization with the Ultrasling® Quadrant (DJO Global Switzerland Sàrl, Ecublens, Switzerland) shoulder brace after surgical treatment
Study NCT05960838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bledsoe ARC®
Description: Immobilization with the Bledsoe ARC® (Breg Inc., Carlsbad, CA USA) brace after surgical treatment
Study NCT05634330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise treatment
Description: core stabilization exercise
Study NCT04903626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (GLE/PIB)
Description: Oral tablets
Study NCT06158867 — intervention group
Intervention type: DEVICE
Intervention: FMD WK
Description: micro-needle patches containing active anti-wrinkle ingredients
Study NCT06452771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-ANG3
Description: Administered subcutaneous (SC) injection
Study NCT06452771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered SC injection
Study NCT05089370 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab
Description: Activation of the RIG-I innate immune pathway and increased expression of tumor antigens and pro-immune genes during Nivolumab treatment may enhance the frequency and activity of anti-tumor immune cells (CD4+ and CD8+ T-cells, NK cells) and reduce the frequency and activity of immunosuppressive cells (MDSCs, Tregs) (1-4), increasing the overall effectiveness and success of Nivolumab treatment. This pilot clinical trial will demonstrate whether combinatorial immunotherapeutic approaches that target epigenetic immune repression and RIG-I activity can favorably alter the tumor immune cell microenvironment and benefit mucosal melanoma patients.
Study NCT05160701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medherent
Description: Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.
Study NCT05160701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medherent
Description: Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.
Study NCT05526755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg/40 mg
Description: Participants will receive osimertinib (80 mg or 40 mg orally, once daily).
Study NCT05973006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
Description: Coformulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 µg antigen and 100 µg adjuvant per mL. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg antigen with 50 µg Matrix-M adjuvant.
Study NCT05973006 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
Description: A site-mixed bivalent vaccine prepared by combining 0.25 mL of NVX-CoV2373 and 0.25 mL NVX-CoV2601. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg total antigen (2.5 µg prototype antigen + 2.5 µg Omicron XBB.1.5 antigen) with 50 µg Matrix-M adjuvant.
Study NCT06289400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic field application
Description: The applicator (Size: 15x15 cm) has placed 1-3 cm above the skin surface at the painful area. During the treatment, treatment has applied with ready-made protocols included in the device.
Study NCT06289400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Within the scope of conventional treatment, hotpack application, transcutaneous electrical stimulation (TENS), interferential current and ultrasound treatment modalities will be applied. In addition, strengthening exercises will be applied to the muscles around the hip and knee and stretching exercises will be applied to the short muscle groups.
Study NCT06289400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Within the scope of conventional treatment, hotpack application, transcutaneous electrical stimulation (TENS), interferential current and ultrasound treatment modalities will be applied. In addition, strengthening exercises will be applied to the muscles around the hip and knee and stretching exercises will be applied to the short muscle groups.
Study NCT05221645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD 1. Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies. Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of indications because of its mechanism of action to bind the PD-1 receptor on the T cell.
Study NCT05221645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab is a chimeric mouse/human monoclonal antibody that binds to CD20, on pre-B and mature B lymphocytes and eliminates these cells potentially via a number of different mechanisms. Anti-CD20 mAbs, like rituximab, are classified by their CD20-binding characteristics, ability to induce complement-dependent cytotoxicity (CDC), and immune effector cell effects.
Study NCT05221645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a chimeric mouse/human monoclonal antibody that binds to CD20, on pre-B and mature B lymphocytes and eliminates these cells potentially via a number of different mechanisms. Anti-CD20 mAbs, like rituximab, are classified by their CD20-binding characteristics, ability to induce complement-dependent cytotoxicity (CDC), and immune effector cell effects.
Study NCT05221645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
Study NCT05221645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
Study NCT05221645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
Study NCT05221645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
Study NCT05221645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.